The prognostic roles of circulating ALDH1+ tumor cell in the patients with non-small cell lung cancer

Shen, Tian; Xing, Yue; Pu, Xia

doi:10.1042/bsr20180914

Cited by 6 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The collection of material for biopsy is a rather painful intervention. Notably, prognostic potential of ALDH1 + CTC in patients with BC was suggested in the literature [20][21][22]. ALDH expression by circulating tumor cells correlates with poor clinical outcome, metastatic progression, and the response to therapy in patients with metastatic breast cancer [22].…”

Section: Resultsmentioning

confidence: 99%

Cancer Stem Cells and Somatic Stem Cells as Potential New Drug Targets, Prognosis Markers, and Therapy Efficacy Predictors in Breast Cancer Treatment

et al. 2021

View full text Add to dashboard Cite

New drug targets, markers of disease prognosis, and more efficient treatment options are an unmet clinical need in breast cancer (BC). We have conducted a pilot study including patients with luminal B stage breast cancer IIA–IIIB. The presence and frequency of various populations of cancer stem cells (CSC) and somatic stem cells were assessed in the blood, breast tumor tissue, and normal breast tissue. Our results suggest that patients with BC can be divided into two distinct groups based on the frequency of aldehyde dehydrogenase positive cells (ALDH1+ cells) in the blood (ALDH1hi and ALDH1low). In the ALDH1hi cells group, the tumor is dominated by epithelial tumor cells CD44+CD24low, CD326+CD44+CD24−, and CD326−CD49f+, while in the ALDH1low cells group, CSCs of mesenchymal origin and epithelial tumor cells (CD227+CD44+CD24− and CD44+CD24−CD49f+) are predominant. In vitro CSCs of the ALDH1low cells group expressing CD326 showed high resistance to cytostatics, CD227+ CSCs of the ALDH1hi cells group are sensitive to cytostatics. Epithelial precursors of a healthy mammary gland were revealed in normal breast tissue of patients with BC from both groups. The cells were associated with a positive effect of chemotherapy and remission in BC patients. Thus, dynamic control of their presence in blood and assessment of the sensitivity of CSCs to cytostatics in vitro can improve the effectiveness of chemotherapy in BC.

show abstract

Section: Resultsmentioning

confidence: 99%

Cancer Stem Cells and Somatic Stem Cells as Potential New Drug Targets, Prognosis Markers, and Therapy Efficacy Predictors in Breast Cancer Treatment

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Mannoor et al found that SNORD1C was expressed at higher levels in non-small cell lung cancer cells that were ALDH1+ compared to those that were ALDH1- [ 11 ]. ALDH1+ tumor cells are believed to have higher proliferation rates, self-renewal capacity, and tumorigenic potential in vivo , which constitute important causes of cancer recurrence [ 12 , 13 ]. Therefore, SNORD1C may have a driving effect on non-small cell lung cancer.…”

Section: Introductionmentioning

confidence: 99%

Overexpression of small nucleolar RNA SNORD1C is associated with unfavorable outcome in colorectal cancer

et al. 2021

View full text Add to dashboard Cite

Colorectal cancer (CRC) is the second most incident cancer and third leading cause of cancer-related mortality worldwide. Small nucleolar RNAs (snoRNAs) are small non-coding RNAs located in the nucleoli of cells, and play key roles in multiple cancers. However, the role of serum snoRNAs in CRC remains unknown. We analyzed the expression of the snoRNA SNORD1C in the serum of patients with CRC using quantitative real-time polymerase chain reaction (qRT-PCR) (n = 122). The receiver operating characteristic (ROC) curves were estimated, and the area under the ROC curve (AUC) was calculated. Gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) analysis of co-expressed genes was performed using the database for annotation, visualization, and integrated discovery (DAVID), and visualized by R language. The results showed that the expression of SNORD1C in patients with CRC (n = 122) was significantly higher than that in normal individuals (n = 50) and patients with benign colorectal disease (n = 33) ( P < 0.05). The overexpression of serum SNORD1C was related to poor tissue differentiation and high carcinoembryonic antigen (CEA) levels ( P < 0.05). In the ROC curve analysis, SNORD1C serum expression combined with CEA offered better predictive value for the diagnosis of CRC (AUC = 0.838) compared with SNORD1C (AUC = 0.748) or CEA (AUC = 0.715) alone. High expression of SNORD1C was found to be closely associated with prognosis and unfavorable outcomes in patient with CRC. Therefore, serum SNORD1C may be a noninvasive tumor biomarker for diagnosis of CRC.

show abstract

“…Their levels were inversely correlated with serum tumor necrosis factor-related apoptosis-inducing ligand (sTRAIL) levels, which have been associated with a tumor suppressive effect [ 33 ]. In another study, sTRAIL was negatively correlated with ALDH1+ cells, the latter being a different marker which can be used for NSCLC CTSCs characterization [ 34 ].…”

mentioning

confidence: 99%

Circulating cancer stem cells: an interesting niche to explore

Papaccio

2020

Exploration of Targeted Anti-Tumor Therapy

View full text Add to dashboard Cite

The prognostic roles of circulating ALDH1+ tumor cell in the patients with non-small cell lung cancer

Cited by 6 publications

References 16 publications

Cancer Stem Cells and Somatic Stem Cells as Potential New Drug Targets, Prognosis Markers, and Therapy Efficacy Predictors in Breast Cancer Treatment

Cancer Stem Cells and Somatic Stem Cells as Potential New Drug Targets, Prognosis Markers, and Therapy Efficacy Predictors in Breast Cancer Treatment

Overexpression of small nucleolar RNA SNORD1C is associated with unfavorable outcome in colorectal cancer

Circulating cancer stem cells: an interesting niche to explore

Contact Info

Product

Resources

About